Disaccharide composition of glycosaminoglycan chains in growing vascular endothelial cells in culture after exposure to lead

Journal of Health Science

Volumn 50, Issue 6, 2004, Pages 660-665

  Fujiwara, Yasuyuki ^a   Kaji, Toshiyuki ^a   Plaas, Anna H ^b  

^a HOKURIKU UNIVERSITY   (Japan)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Atherosclerosis; Chondroitin dermatan sulfate; Endothelial cell; Heparan sulfate; Lead; Proteoglycan

Indexed keywords

2 O SULFATED HEXURONIC ACID N SULFATED GLUCOSAMINE; CHONDROITIN SULFATE; CORE PROTEIN; DERMATAN SULFATE; DISACCHARIDE; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEXURONIC ACID N ACETYLGLUCOSAMINE; HEXURONIC ACID N SULFATED GLUCOSAMINE; LEAD; METAL; PERLECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE ANALYSIS; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; EXPOSURE; EXTRACELLULAR MATRIX; MOLECULE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; VASCULAR ENDOTHELIUM;

ANIMALIA;

EID: 24744436974     PISSN: 13449702     EISSN: None     Source Type: Journal    
DOI: 10.1248/jhs.50.660     Document Type: Article

References (25)

1. Givol, D. and Yayon, A. (1992) Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J., 6, 3362-3369.
2. Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P. and Ornitz, D. M. (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell, 64, 841-848.
3. Rapraeger, A. C., Krufka, A. and Olwin, B. B. (1991) Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science, 52, 1705-1708.
4. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E. and Leder, P. (1992) Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol., 12, 240-247.
5. Wight, T. N. (1980) Vessel proteoglycans and thrombogenesis. Prog. Hemost. Thromb., 5, 1-39.
6. Guimond, S., Maccarana, M., Olwin, B. B., Lindahl, U. and Rapraeger, A. C. (1993) Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem., 268, 23906-23914.
7. Pye, D. A. and Kumar, S. (1998) Endothelial and fibroblast cell-derived heparan sulphate bind with differing affinity to basic fibroblast growth factor. Biochem. Biophys. Res. Commun., 248, 889-895.
8. Iozzo, R. V. (1994) Perlecan: a gem of a proteoglycan. Matrix Biol., 14, 203-208.
9. Nugent, M. A. and Iozzo, R. V. (2000) Fibroblast growth factor-2. Int. J. Biochem. Cell Biol., 32, 115-120.
10. Aviezer, D., Hecht, D., Safran, M., Eisinger, M., David, G. and Yayon, A. (1994) Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell, 79, 1005-1013.
11. Jayson, G. C., Lyon, M., Paraskeva, C., Turnbull, J. E., Deakin, J. A. and Gallagher, J. T. (1998) Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J. Biol. Chem., 273, 51-57.
12. Dingwall-Fordyce, I. and Lane, R. E. (1963) A follow-up study of lead workers. Br. J. Ind. Med., 20, 313-315.
13. Revis, N. W., Zinsmeister, A. R. and Bull, R. (1981) Atherosclerosis and hypertension induced by lead and cadmium ions: an effect prevented by calcium ion. Proc. Natl. Acad. Sci. U.S.A., 78, 6494-6498.
14. Lal, B., Murthy, R. C., Anand, M., Chandra, S. V., Kumar, R., Tripathi, O. and Srimal, R. C. (1991) Cardiotoxicity and hypertension in rats after oral lead exposure. Drug Chem. Toxicol., 14, 305-318.
15. Schwartz, J. (1991) Lead, blood pressure, and cardiovascular disease in men and women. Environ. Health Perspect., 91, 71-75.
16. Houtman, J. P. (1996) Trace elements and cardiovascular diseases. J. Cardiovasc. Risk, 3, 18-25.
17. Kaji, T. (2004) Cell biology of heavy metal toxicity in vascular tissue. Yakugaku Zasshi, 124, 113-120.
18. Ross, R., Glomset, J. and Harker, L. (1997) Response to injury and atherosclerosis. Am. J. Pathol., 86, 675-684.
19. Fujiwara, Y. and Kaji, T. (2000) Inhibition of the repair of injured endothelial cell monolayers by lead and its possible mechanisms. J. Health Sci., 46, 1-4.
20. Kissane, J. M. and Robins, E. (1958) The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system. J. Biol. Chem., 233, 184-188.
21. Kaji, T., Fujiwara, Y., Hoshino, M., Yamamoto, C., Sakamoto, M. and Kozuka, H. (1995) Inhibitory effect of lead on the proliferation of cultured vascular endothelial cells. Toxicology, 95, 87-92.
22. 1 in cultured bovine aortic endothelial cells. J. Biol. Chem., 275, 1463-1470.
23. Knox, S., Merry, C., Stringer, S., Melrose, J. and Whitelock, J. (2002) Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J. Biol. Chem., 277, 14657-14665.
24. Feitsma, K., Hausser, H., Robenek, H., Kresse, H. and Vischer, P. (2000) Interaction of thrombospondin-1 and heparan sulfate from endothelial cells. Structural requirements of heparan sulfate. J. Biol. Chem., 275, 9396-9402.
25. Fujiwara, Y. and Kaji, T. (1999) Lead inhibits the core protein synthesis of a large heparan sulfate proteoglycan perlecan by proliferating vascular endothelial cells in culture. Toxicology, 133, 159-169.